© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
March 09, 2015
Treatment with LPCN 1021 restored and maintained testosterone levels at rates comparable to approved non-oral products.
Study results show that men with stable coronary heart disease or acute coronary syndrome who received testosterone replacement therapy did not experience higher rates of major adverse cardiovascular events than men who did not receive testosterone replacement therapy.
March 08, 2015
Researchers reported no association between endogenous testosterone and incident stroke and ischemic changes in men evaluated via brain MRI imaging.
Study results presented at ENDO 2015 suggest that some risk factors associated with cardiovascular disease are regulated by testosterone and estradiol, others (such as changes in LDL cholesterol and blood pressure) are not.
Greater Baseline Retinal Nonperfusion Linked to Worsening Diabetic Retinopathy
John J. Miller, MD: A New Era For Psychiatric Medications
Aluminum Exposure Induces Cytokine Secretion in Crohn’s Disease Colons